Taking Aim at Cancer Costs
To promote the use of lower-cost generic chemotherapy drugs, Calabria says HAP has worked to increase—not decrease—the provider reimbursement for generic oncology drugs. Cutting reimbursements would be a "disincentive" for physicians to use generics, according to Calabria.
"This isn't a utilization management program," he explains. "We don't want to discourage generic usage by not reimbursing correctly."
Calabria acknowledges that oncology cost and treatment management is a "new frontier. It's emotional." Among the hoped-for outcomes of the program is that the pathways provide physicians and patients with the clinical support they need to feel more comfortable with getting ready for end-of-life care. "At some point we need to stop treatment when there's no support for it anymore."
Calabria expects the HAP program to get underway later this year.
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- 3 Traits Personality Assessments Can't Reveal
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CHS Hacked, 4.5M Patient Records Compromised
- CFO Exchange: Healthcare Leaders Share 5 Innovative Ideas
- Business Roundup: M&A Activity Down Slightly in First Half of 2014
- Large Employers Trimming Healthcare Spending
- CNO on Hospital Redesign: 'You Can't Over-Communicate'